期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

琥珀酸去甲文拉法辛的药理及临床研究 被引量：4

Pharmacological and clinical studies of desvenlafaxine succinate
原文传递
导出
摘要 琥珀酸去甲文拉法辛(desvenlafaxine succinate,商品名为Pristiq)于2008年2月29日经美国FDA批准上市,由美国Wyethpharms inc公司生产,用于治疗重症抑郁性障碍(MDD)。文中对该药的药理作用及临床应用等进行了综述。 Desvenlafaxine succinate, produced by Wyethpharms Inc, is approved by the US FDA for the treatment of major depression disorder （ MDD）. The paper reviews the pharmacological effect and clinical studies of desvenlafaxine succinate.
作者 李灵 曹国颖 毕开顺 胡欣
机构地区 沈阳药科大学 卫生部北京医院
出处 《中国新药杂志》 CAS CSCD 北大核心 2009年第16期1483-1485,1492,共4页 Chinese Journal of New Drugs
关键词 去甲文拉法辛 药理作用 重症抑郁性障碍 抑郁症 临床研究 desvenlafaxine succinate pharmacological effect major depression disorder （MDD） depressive disorder clinical study
分类号 R971.43 [医药卫生—药品]
  • 相关文献

参考文献13

  • 1GREDEN JF. Physical symptoms of depression: unmet needs[J]. Clin Psychiatr2, 2003,64( S7 ) :5 - 11.
  • 2NEMEROFF CB, SCHATZBERG AF, GOLDSTEIN DJ, et al. Duloxetine for the treatment of major depressive disorder [ J ]. Psychopharmacol Bull, 2002,36 ( 4 ) : 106 - 132.
  • 3NELSON JC, MAZURE CM, JATI,OW Pl,et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression : a double-blind, randomized study [ J ]. Biol Psychiatry,2004,55 ( 3 ) :296 - 300.
  • 4TRIVEDI MH, RUSH AJ, WISNIEWSKI SR. et al. Evaluation of outcomes wilh citalopram for depression using measurement- based care in STAR * D: implications for clinical practice [ J ]. Am J Psychiatry,2006,163 (1 ) :28 - 40.
  • 5CLEMENT EM,ODONTIADIS J,FRANKLIN M. Simultaneous measurement of venlafaxine and its major metabolite, oxydes- methylvenlafxine, in human plasma by high-performance liquid chromalography wilh coulometric deteelion and utilisation of solidphase extraction[ J ]. J Chromatogr B Biomed Sci Appl, 1998,705 (2) :303 -308.
  • 6SEPTIEN-VELEZA E, PITROSKY B, PADMANABHAN SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine suecinate in the treatment of major depressive disorder [ J].Int Clin Psychopharmacol,2007,22 ( 6 ) :338 - 347.
  • 7DEECHER DC, BEYER CE, JOHNSTON G, et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor[ J ]. J Pharmacol Eap Ther,2006,318 ( 2 ) :657 - 665.
  • 8Wyeth Pharmaceuticals Inc. ttighlights of preseribing information: prescribing information for Pristiq (desvenlafaxine) [ EB/ OL]. FDA, 2008. [2008 - 10 -28]. http://www, fda. gov/ eder/foi/label/2008/0219921b1. pdf.
  • 9MUTH EA, MOYER JA, HASKINS JT, et al. Biochemical, europhysiological,and behavioral effects of WU-45233 and other identified metabolites of the antidepressanl venlafaxine [ J]. Drug Dev Res,1991, 23(2) : 191 - 199.
  • 10SORBERA LA, BOLOS J, SERRADELL N ,et al. Desvenlafaxine succinate [ J ]. Drugs Fut,2006,31 (4) : 304 - 509.

同被引文献26

  • 1李洁,马崔.文拉法辛的药理特点及临床应用[J].山东精神医学,2005,18(4):276-279. 被引量：20
  • 2Nichols AI, Fatato P, Shenouda M, et al.The effects of des- venlafaxine and paroxetine on the pharmacokinetics of the cytochrome P4502D6 substrate desipramine in healthy adults [J].J Clin Pharmaco, 2009,49 ( 2 ) : 219.
  • 3Sorbera LA, Bolos J, Serradell N, et al.Desvenlafaxine suc- cinate [J].Drugs Fut, 2006,31 (4) : 304.
  • 4Kamath J, Handratta V. Desvenlafaxine succinate for ma-jor depressive disorder: a critical review of the evidence [J].Expert Rev Neurotherapeutics, 2008,8 (12) : 1 787.
  • 5Patroneva A, Connolly SM, Fatato P, et aLAn assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects[J]. Drug Metab Dis- pos,2008,36(12) :2 484.
  • 6Sproule BA, Hazra M, Pollock BG.Desvenlafaxine succi- nate for major depressive disorder[J].Drugs Today, 2008, 44(7):475.
  • 7Liebowitz MR, Manley AL, Padmanabhan SK, et a/.Effica- cy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive dis- order [J].Curr MedRes Opin, 2008,24(7) : 1 877.
  • 8Clayton AH, Komstein SG, Rosas G, et al. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depres- sive disorder [J]. CNS Spectrums, 2009,14(4) : 183.
  • 9Archer DF, Seidman L, Constantine G , et al. A dou- ble-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause[J]. Am J Obstet Gynecol,2009,200(2) : 172.
  • 10Archer DF, Dupont CM, Constantine GD, et al. Desven- lafaxine for the treatment of vasomotor symptoms associ- ated with menopause: a double-blind, randomized, place- bo-controlled trial of efficacy and safety [J]. Am J Obstet Gynecol, 2009,200(3) : 238.

引证文献4

二级引证文献10

中国新药杂志
2009年 第16期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部